Hip & pelvis

The Korean Hip Society (대한고관절학회)
권호 표지

Risk Factors for Osteonecrosis of the Femoral Head in Patients with Heamatologic diseases

혈액질환 환자에서 대퇴골두 무혈성 괴사의 위험인자

  • Kim, Yong-Sik (Department of Orthopedic Surgery, Kangnam St. Mary’s Hospital, The Catholic University) ;
  • Yune, Young-Phil (Department of Orthopedic Surgery, Sun General Hospital) ;
  • Lim, Young-Wook (Department of Orthopedic Surgery, Kangnam St. Mary’s Hospital, The Catholic University) ;
  • Kim, Dong-Yeob (Department of Orthopedic Surgery, St. Mary’s Hospital, The Catholic University) ;
  • Kwon, Soon-Yong (Department of Orthopedic Surgery, St. Mary’s Hospital, The Catholic University)
  • 김용식 (가톨릭대학교 의과대학 강남성모병원 정형외과) ;
  • 윤영필 (대전 선병원 정형외과) ;
  • 임영욱 (가톨릭대학교 의과대학 강남성모병원 정형외과) ;
  • 김동엽 (가톨릭대학교 의과대학 성모병원 정형외과) ;
  • 권순용 (가톨릭대학교 의과대학 성모병원 정형외과)
  • Published : 2009.03.31

⟨ Previous Next ⟩

Abstract

Purpose: We aimed to clarify the risk factors associated with the development of ONFH by comparing patients with hematologic diseases and osteonecrosis of the femur head (ONFH) to those patients without ONFH and who have hematologic diseases Materials and Methods: The study population was limited to the patients admitted to our Hematology-Oncology department from 1 January 1994 to 31 May 2007. The patients were divided into 2 groups (those with ONFH, 54 patients and those without ONFH, 54 patients) and the risk factors for ONFH were evaluated by a comparative analysis. We analyzed the effect of a history of bone marrow transplantation (BMT), graft-versus-host disease (GVHD), total body radiation (TBI) and the amount of steroid used as the risk factors for ONFH. Results: On the multiple logistic regression analysis, a total steroid use of >1.5 g/BMI was statistically identified as a significant risk factor for ONFH. The history of BMT and TBI were not statistically correlated with the development of ONFH. Among the patients with BMT, allogenic BMT and a history of GVHD were not statistically correlated with the development of ONFH on the multiple logistic regression analysis. Conclusion: Patients with hematologic diseases and who have used steroid >1.5g/BMI should carefully observed because they are more likely to develop ONFH.

목적: 혈액질환 환자를 대상으로 대퇴골두 무혈성괴사가 발생한 군과 발생하지 않은 군을 비교 분석하여 대퇴골두 무혈성괴사와 연관된 위험인자를 밝혀 보고자 한다. 대상 및 방법: 1994년 1월 1일부터 2007년 5월 31일까지 혈액종양 내과에서 입원 치료한 혈액질환 환자를 대상으로 대퇴골두 무혈성 괴사가 발생한 군(54명)과 발생하지 않은 군(54명)을 대상으로 골수이식의 종류, 이식편 대 숙주질환, 전신 방사선조사, 스테로이드 사용량 등을 위험 요소로 분석하였다. 결과: 복합회귀분석에서 위험 요소 중 총 스테로이드 사용량 1.5 g/BMI 이상인 경우 유의한 위험인자로 분석되었다. 골수 이식의 시행여부와 전신방사선 조사 여부는 두 군에서 통계적으로 유의하지 않은 결과를 보였다. 골수 이식을 시행한 경우에 복합회귀분석에서 이식편 대 숙주질환의 발생 유무와 동종이식의 시행여부를 조사해 보았을 때 통계적으로 유의하지 않은 결과를 보였다. 결론: 혈액 질환 환자에서 1.5g/BMI 이상의 스테로이드를 사용한 경우는 대퇴골두 무혈성 괴사의 가능성이 높으므로 주의 깊은 추시가 필요하다.

Keywords

References

  1. Andrykowski MA, Altmaier EM, Barnett RL, et al.: The quality of life in adult survivors of allogeneic bone marrow transplantation: Correlates and comparision with matched renal transplant recipients. Transplantation, 50: 399-406, 1990. https://doi.org/10.1097/00007890-199009000-00009
  2. Atkinson K, Cohen M, Biggs J: Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft-versus-host disease after marrow transplantation: effective therapy with hip arthroplasty. Bone Marrow Transplant, 2: 421-426, 1987.
  3. Cruess, RL: Osteonecrosis of bone: current concepts as to etiology and pathogenesis. Clinics in Orthopedics, 208: 30-39, 1986.
  4. Ebeling PR, Thomas DM, Erbans B, Hopper JL, Szer J, Grigg A: Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res, 14: 342-350, 1999. https://doi.org/10.1359/jbmr.1999.14.3.342
  5. Enright H, Haake R, Weisdorf D: Avascular necrosis of bone: a common serious complication of allogenic bone marrow transplantation. Am J Med, 89: 733-738, 1990. https://doi.org/10.1016/0002-9343(90)90214-X
  6. Fink JC, Leisenring WM, Sullivan KM, Sherrard DJ, Weiss NS: Avascular necrosis of following bone marrow transplantation: a case-control study. Bone, 22: 67-71, 1998. https://doi.org/10.1016/S8756-3282(97)00219-6
  7. Felson DT, Anderson JJ: Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet, I: 902-906, 1987.
  8. Glucksberg H, Storb R, Fefer A, et al.: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplatation, 18: 295-304, 1974. https://doi.org/10.1097/00007890-197410000-00001
  9. Grotz W, Breitenfeldt K, Cybulla M: Immunosuppression and skeletal disorders. Transplant Proc, 33: 992-993, 2001. https://doi.org/10.1016/S0041-1345(00)02300-9
  10. Kolb HJ, Bender-Gotze C: Late complications after allogenic bone marrow transplantation for leukemia. Bone Marrow Transplant, 6: 61-72, 1990.
  11. Mankin HJ: Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med, 326: 1473-1479,1992. https://doi.org/10.1056/NEJM199205283262206
  12. Marsh JC, Zomas A, Hows JM, Chapple M, Gordon-Smith EC: Avascular necrosis after treatment of aplastic anemia with antilymphocyte globulin and high-dose methylprednisolone. Br J Heamatol, 84: 731-735, 1993. https://doi.org/10.1111/j.1365-2141.1993.tb03153.x
  13. Marymont JV, Kaufman EE: Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop Relat Res, 204: 150-153, 1986.
  14. Mont MA, Hungerford DS: Non traumatic avascular necrosis of the femoral head. J Bone Joint Surg, 77-A: 459-474, 1995.
  15. Mori A, Hashino S, Kobayashi S, et al.: Avascular necrosis in the femoral head secondary to bone marrow infarction in patient with graft-versus-host disease after unrelated bone marrow transplantation. Ann Hematol, 80: 238-242, 2001. https://doi.org/10.1007/s002770000253
  16. Russel JA, Blahey WB, Stuart TA, Edwards G, Card RT: Avascular necrosis of bone in bone marrow transplant patients. Med Pediatr Oncol, 17: 140-143, 1989. https://doi.org/10.1002/mpo.2950170213
  17. Sato K, Satomi S, Oguma S, et al.: Relationship between aseptic necrosis of femoral head bone and immunosuppression therapy, especially CsA administration. Nippon Geka Gakkai Zasshi, 94: 832-839, 1993.
  18. Socie G, Cahn JY, Carmelo J, et al.: Avascular necrosis of bone after allogenic bone marrow transplantation: analysis of risk factor for 4388 patients by the Societe Francaise de Greffe de Moelle(SFGM). Br J Haematol, 97: 865-870, 1997. https://doi.org/10.1046/j.1365-2141.1997.1262940.x
  19. Socie G, Selimi F, Sedel L, et al.: Avascular necrosis of bone after allogenic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol, 86: 624-628, 1994. https://doi.org/10.1111/j.1365-2141.1994.tb04795.x
  20. Stern JM, Sullivan KM, Ott SM, et al.: Bone density loss after allogenic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant, 7: 257-264, 2001 https://doi.org/10.1053/bbmt.2001.v7.pm11400947
  21. Torii Y, Hasegawa Y, Kubo T, et al.: Osteonecrosis of the femoral head after allogenic bone marrow transplantation. Clin Orthop Relat Res, 382:124-132, 2001. https://doi.org/10.1097/00003086-200101000-00019
  22. Thomas ED: Frontiers on bone marrow transplantation.: fetal hematopoiesis. Blood Cell, 17: 257-441, 1991.
  23. Thomas ED, Buckner CD, Banaji M, et al.: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood, 49: 511-533, 1977.
  24. Vande Berg BC, Malghem J, Lecouvet FE, et al.: Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum, 42: 1405-1411, 1999. https://doi.org/10.1002/1529-0131(199907)42:7<1405::AID-ANR14>3.0.CO;2-W
  25. Vreden SG, Hermus AR, van Liessum PA, Pieters GF, Smals AG and Kloppenborg PW: Aseptic bone necrosis in patients on glucocosteroid replacement therapy. Neth J Med, 39: 153-157, 1991.
  26. Wiesmann A, Pereira P, Bohm P, Faul C, Kanz L and Einsele H: Avascular necrosis of bone following allogenic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant, 22: 565-569, 1998. https://doi.org/10.1038/sj.bmt.1701374